The latest biotech news

News and Trends 16 Nov 2016

Cell Therapies: Is Commercialization holding back a Breakthrough?

How far away is biotech from a breakthrough with cell and gene therapy? While these therapies have the potential to be the most effective on the market, they are still a long way away from that point, according to a pair of expert panels at BIO Europe last week. Everyone in cell therapy knows the […]

November 16, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 15 Nov 2016

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment? Sanofi Genzyme signed a deal with Alnylam back in 2014 to develop RNAi therapies. Now, despite the general discouragement in RNAi technology, Sanofi has decided to go ahead and […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

CRISPR meets RNAi: a whole new Targeted Therapy

Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using its RNAi delivery expertise. How does it plan to find a space in this challenging and competitive field? Based on the UK’s golden triangle, Silence Therapeutics develops RNAi therapies to treat cancer. Now, it will be applying its targeted RNA delivery […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

Red Blood Cells as Cancer Drug Carriers: Market Approval gets Delayed

Erytech will have to provide additional data before re-applying for market approval in Europe for Graspa. This leukemia therapy uses red blood cells to deliver an enzyme that starves tumors to death. Erytech is a biotech from Lyon with a visionary approach to treat cancer: using red blood cells as drug carriers. Last year, the company […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

How much of a Gamble is Investing in CRISPR?

CRISPR is going to change a lot in the life science industry and is perceived as THE discovery of the 21st century. Within the past 6 months, 3 companies went public, raising between €50M and €100M each (with valuation close to the billion), to bring about the CRISPR revolution. But the problem is, there is absolutely […]

November 15, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 14 Nov 2016

Ask the Biotech Recruiter: Time-Saving Tricks to Reel in a New Hire

Time is of the essence in a recruitment. The biotech recruiters at Pact & Partners know how to manage it efficiently without missing anything! Hiring a top talent is an exhausting and time-consuming process, and it can be tempting to rush through it once you think you’ve found a match. But this attitude can create more […]

November 14, 2016 - 6 minutesmins - By External Contributor

News and Trends 14 Nov 2016

Meet one of the Most Impressive French Biotech Entrepreneurs

The previous executive profiles we did, namely on Joern Aldag and Philippe Dro, are hard acts to follow, but Bernard Gilly was more than up to it. Bernard has a broad set of achievements for a broad set of lessons and takeaways. Here are the major ones. You might have seen Bernard Gilly’s name in the […]

November 14, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 14 Nov 2016

USB key Diagnostic could help manage HIV Treatment Anywhere

A new method of gene sequencing has brought us an HIV diagnostic on a “USB stick”, which determines the levels of the virus with one drop of blood and in under 30 minutes. Once perfected, the technology could be the tool for HIV management as glucose meters are for diabetes. While pharma and research work […]

November 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

Screenshot 2016 11 08 at 3.21.24 PM e1478614975174

News and Trends 12 Nov 2016

The sound of this Spider Silk Violin surprises Expert Musicians

Last week, Imperial College London hosted the International Student Innovation Awards. The winner astonished everyone with a violin made with spider silk. Luca Alessandrini was awarded the £10,000 prize for the design of a biomaterial-based violin that can be engineered to customize the final sound. With the new funds and a patent filed, the designer is now looking for co-founders to […]

November 12, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Nov 2016

UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials

The FDA puts one of Adaptimmune‘s TCR trials on a partial hold, pending more information about the production of its cell therapy. It’s more waves for the Biotech’s financial rocking boat. Oxford-based Adaptimmune is one of the European players in TCR therapies. Besides being listed on the NASDAQ, it got GSK on board on a €311M […]

November 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 10 Nov 2016

Evotec chooses Oxford as Proving Ground for Academia-Industry Bridge

The German CRO has struck a deal with the University of Oxford to test a model framework for bringing academic research to the clinic faster. Evotec started out as a service provider in Hamburg, but thanks to former CEO Jörn Aldag, it has blossomed into a company that specializes in transforming newly discovered therapies into […]

November 10, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 10 Nov 2016

European Biotech is working hard to Beat back Melanoma

Immunocore and Pierre Fabre have been representing Europe in this years’ Society for Melanoma Research Congress. This type of cancer may have its days counted! This week, scientists from around the globe met at the MRC to get an update on what’s going on in the fights against melanoma, the least common but most deadly skin […]

November 10, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Cell Therapies: Is Commercialization holding back a Breakthrough?

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

CRISPR meets RNAi: a whole new Targeted Therapy

Red Blood Cells as Cancer Drug Carriers: Market Approval gets Delayed

How much of a Gamble is Investing in CRISPR?

Ask the Biotech Recruiter: Time-Saving Tricks to Reel in a New Hire

Meet one of the Most Impressive French Biotech Entrepreneurs

USB key Diagnostic could help manage HIV Treatment Anywhere

The sound of this Spider Silk Violin surprises Expert Musicians

UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials

Evotec chooses Oxford as Proving Ground for Academia-Industry Bridge

European Biotech is working hard to Beat back Melanoma

Subscribe to our newsletter to get the latest biotech news!